Výsledky vyhledávání - "Lars Bardtrum"

Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators

Autor: Kathleen M. Dungan, Lars Bardtrum, Erik Christiansen, Johanna Eliasson, Linda Mellbin, Vincent C. Woo, Tina Vilsbøll

Publikováno v: Diabetes Therapy.

Introduction A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA1c (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide ve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4bc9a514bf2b1c0eee6f5f434a748b2
https://doi.org/10.1007/s13300-023-01413-5

Zobrazit plný text záznamu

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL

Autor: Ulrik Pedersen-Bjergaard, Wendy Lane, Athena Philis-Tsimikas, Simon Heller, Lars Bardtrum, Carol Wysham, Signe Harring

Publikováno v: Diabetes, Obesity & Metabolism
Philis-Tsimikas, A, Lane, W, Pedersen-Bjergaard, U, Wysham, C, Bardtrum, L, Harring, S & Heller, S 2020, ' The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL ', Diabetes, Obesity and Metabolism, vol. 22, no. 5, pp. 779-787 . https://doi.org/10.1111/dom.13954

Aim\ud \ud Treat‐to‐target, randomized controlled trials have confirmed lower rates of hypoglycaemia at equivalent glycaemic control with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 1 (T1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3740a6ed8196524ce9164291eb92b589
https://doi.org/10.1111/dom.13954

Zobrazit plný text záznamu

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

Autor: Vanita R. Aroda, Martin Haluzik, Lars Bardtrum, Selcuk Dagdelen, Giorgio Sesti, Petra Őrsy, Martín Rodríguez, Natalie Halladin

Publikováno v: Diabetes, Obesity & Metabolism

This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104‐week DUAL VIII durability trial (NCT02501161). Participan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe4c7e38e100e0e2b1063cd8e568386
http://europepmc.org/articles/PMC7187233

Zobrazit plný text záznamu

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials

Autor: Bernt Johan von Scholten, Erik Christiansen, Matthias von Herrath, Two Investigators, Lars Bardtrum, Thomas F. Dejgaard, Sten Madsbad, Frederik Flindt Kreiner, Chantal Mathieu, One

Publikováno v: Diabetes Obes Metab
Dejgaard, T F, Scholten, B J V, Christiansen, E, Kreiner, F F, Bardtrum, L, Herrath, M V, Mathieu, C & Madsbad, S 2021, ' Efficacy and Safety of Liraglutide in Type 1 Diabetes by Baseline Characteristics in the ADJUNCT ONE and ADJUNCT TWO Randomized Clinical Trials ', Diabetes, Obesity and Metabolism, vol. 23, no. 12, pp. 2752-2762 . https://doi.org/10.1111/dom.14532

Aims Evaluate 26 weeks’ liraglutide treatment in type 1 diabetes (T1D) by subgroups in the ADJUNCT ONE and TWO trials. Materials and Methods ADJUNCT ONE and TWO were randomized controlled phase 3 trials in 1,398 and 835 participants with T1D treate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e73ed4c35a3647883eb62d7dca7e841c
https://lirias.kuleuven.be/handle/123456789/680609

Zobrazit plný text záznamu

668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events

Autor: Eduard Montanya, Richard E. Pratley, Juris J. Meier, Lars Bardtrum, Alice Y. Cheng, Rikke Mette Agesen, Srikanth Deenadayalan

Publikováno v: Diabetes. 70

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce body weight (BW). Evidence suggests that GLP-1RAs directly modulate appetite and reduce food intake through central mechanisms. However, GLP-1RAs are also associated with gastrointestinal (G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d2469878c14379ada99f2189f783b52
https://doi.org/10.2337/db21-668-p

Zobrazit plný text záznamu

675-P: Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two

Autor: Thomas F. Dejgaard, Frederik Flindt Kreiner, Lars Bardtrum, Sten Madsbad, Bernt Johan von Scholten, Chantal Mathieu, Matthias G. Von Herrath, Erik Christiansen

Publikováno v: Diabetes. 70

We re-evaluated the efficacy and safety of liraglutide, a GLP-1 analog, for use as adjunctive therapy in people with type 1 diabetes (T1D). Results from the two ADJUNCT trials suggested that residual beta-cell function is associated with more pronoun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b487bbfb58c8a87431c9efcd9aa80a5
https://doi.org/10.2337/db21-675-p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání